Interindividual variability in oral antidiabetic drug disposition and response: the role of drug transporter polymorphisms

Bibliography

• International Diabetes Federation website. Available from: http://www.idf.org [Last accessed 30 January 2008]
   Google Scholar
• Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005;365:1333-46
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes: 2008. Diabetes Care 2008;31:S12-54
   PubMed Web of Science ®Google Scholar
• Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147:386-99
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008;31:173-5
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Roots I, Goldammer M, et al. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet 2005;44:1209-25
   PubMed Web of Science ®Google Scholar
• Aquilante CL. Pharmacogenetics of thiazolidinedione therapy. Pharmacogenomics 2007;8:917-31
   PubMed Web of Science ®Google Scholar
• Bozkurt O, de Boer A, Grobbee DE, et al. Pharmacogenetics of glucose-lowering drug treatment: a systematic review. Mol Diagn Ther 2007;11:291-302
   PubMed Web of Science ®Google Scholar
• Moore AF, Florez JC. Genetic susceptibility to type 2 diabetes and implications for antidiabetic therapy. Ann Rev Med 2008;59:95-111
   PubMed Web of Science ®Google Scholar
• Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005;78:260-77
   PubMed Web of Science ®Google Scholar
• Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 2006;27:425-46
   PubMed Web of Science ®Google Scholar
• Bachmakov I, Glaeser H, Fromm MF, et al. Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on OATPs and OCT1. Diabetes 2008 Feb 26 [Epub ahead of print] PMID: 18314419
   PubMedGoogle Scholar
• Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-9
   PubMed Web of Science ®Google Scholar
• Reitman ML, Schadt EE. Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest 2007;117:1226-9
   PubMed Web of Science ®Google Scholar
• Glucophage prescribing information. Bristol-Myers Squibb Company; 2006
   Google Scholar
• Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002;137:25-33
   PubMed Web of Science ®Google Scholar
• Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000;49:2063-9
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
   PubMed Web of Science ®Google Scholar
• Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360-72
   PubMed Web of Science ®Google Scholar
• Hermann LS, Schersten B, Bitzen PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994;17:1100-9
   PubMed Web of Science ®Google Scholar
• Riedel AA, Heien H, Wogen J, et al. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy 2007;27:1102-10
   PubMed Web of Science ®Google Scholar
• Pearson ER, Donnelly LA, Kimber C, et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 2007;56:2178-82
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-12
   PubMed Web of Science ®Google Scholar
• Sambol NC, Chiang J, O'Conner M, et al. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol 1996;36:1012-21
   PubMed Web of Science ®Google Scholar
• Sirtori CR, Franceschini G, Galli-Kienle M, et al. Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther 1978;24:683-93
   PubMed Web of Science ®Google Scholar
• Pentikainen PJ, Neuvonen PJ, Penttila A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 1979;16:195-202
   PubMed Web of Science ®Google Scholar
• Tucker GT, Casey C, Phillips PJ, et al. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 1981;12:235-46
   PubMed Web of Science ®Google Scholar
• Shu Y, Brown C, Castro R, et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Mol Ther 2008;83:273-80
   Google Scholar
• Wang DS, Jonker JW, Kato Y, et al. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 2002;302:510-5
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996;30:359-71
   PubMed Web of Science ®Google Scholar
• Leabman MK, Huang CC, DeYoung J, et al. Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci USA 2003;100:5896-901
   PubMed Web of Science ®Google Scholar
• Kimura N, Masuda S, Tanihara Y, et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 2005;20:379-86
   PubMedGoogle Scholar
• Zhang L, Dresser MJ, Gray AT, et al. Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol 1997;51:913-21
   PubMed Web of Science ®Google Scholar
• Dresser MJ, Leabman MK, Giacomini KM. Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J Pharm Sci 2001;90:397-421
   PubMed Web of Science ®Google Scholar
• Dresser MJ, Xiao G, Leabman MK, et al. Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2). Pharm Res 2002;19:1244-7
   PubMed Web of Science ®Google Scholar
• Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007;117:1422-31
   PubMed Web of Science ®Google Scholar
• Wang DS, Kusuhara H, Kato Y, et al. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol 2003;63:844-8
   PubMed Web of Science ®Google Scholar
• Sakata T, Anzai N, Shin HJ, et al. Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochem Biophys Res Commun 2004;313:789-93
   PubMed Web of Science ®Google Scholar
• Shu Y, Leabman MK, Feng B, et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci USA 2003;100:5902-7
   PubMed Web of Science ®Google Scholar
• Kerb R, Brinkmann U, Chatskaia N, et al. Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics 2002;12:591-5
   PubMedGoogle Scholar
• Shikata E, Yamamoto R, Takane H, et al. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet 2007;52:117-22
   PubMed Web of Science ®Google Scholar
• Fujita T, Urban TJ, Leabman MK, et al. Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm Sci 2006;95:25-36
   PubMed Web of Science ®Google Scholar
• Shu Y, Urban TJ, Leabman MK, et al. PharmGKB submission update: V. PMT submissions of genetic variation in SLC22 family transporters. Pharmacol Rev 2006;58:3-4
   PubMed Web of Science ®Google Scholar
• Florez JC, Jablonski KA, Sun MW, et al. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab 2007;92:1502-9
   PubMed Web of Science ®Google Scholar
• Florez JC, Jablonski KA, Kahn SE, et al. Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. Diabetes 2007;56:531-6
   PubMed Web of Science ®Google Scholar
• Prandin Prescribing Information. Novo Nordisk, Inc.; 2006
   Google Scholar
• Starlix Prescribing Information. Novartis; 2006
   Google Scholar
• Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet 2002;41:471-83
   PubMed Web of Science ®Google Scholar
• Dornhorst A. Insulinotropic meglitinide analogues. Lancet 2001;358:1709-16
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Hassman DR, Madder RD, et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004;27:1265-70
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Neuvonen M, et al. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 2003;46:347-51
   PubMed Web of Science ®Google Scholar
• Niemi M, Neuvonen PJ, Kivisto KT. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 2001;70:58-65
   PubMed Web of Science ®Google Scholar
• Zhang W, He YJ, Han CT, et al. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br J Clin Pharmacol 2006;62:567-72
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Meineke I, Muller G, et al. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Clin Pharmacokinet 2004;43:267-78
   PubMed Web of Science ®Google Scholar
• Thomsen MS, Chassard D, Evene E, et al. Pharmacokinetics of repaglinide in healthy caucasian and Japanese subjects. J Clin Pharmacol 2003;43:23-8
   PubMed Web of Science ®Google Scholar
• McLeod JF. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. Clin Pharmacokinet 2004;43:97-120
   PubMed Web of Science ®Google Scholar
• Konig J, Seithel A, Gradhand U, et al. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 2006;372:432-43
   PubMed Web of Science ®Google Scholar
• Tirona RG, Leake BF, Merino G, et al. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 2001;276:35669-75
   PubMed Web of Science ®Google Scholar
• Kameyama Y, Yamashita K, Kobayashi K, et al. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 2005;15:513-22
   PubMed Web of Science ®Google Scholar
• Kivisto KT, Niemi M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm Res 2007;24:239-47
   PubMed Web of Science ®Google Scholar
• Mwinyi J, Johne A, Bauer S, et al. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 2004;75:415-21
   PubMed Web of Science ®Google Scholar
• Iwai M, Suzuki H, Ieiri I, et al. Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 2004;14:749-57
   PubMedGoogle Scholar
• Maeda K, Ieiri I, Yasuda K, et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 2006;79:427-39
   PubMed Web of Science ®Google Scholar
• Niemi M, Schaeffeler E, Lang T, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004;14:429-40
   PubMedGoogle Scholar
• Kajosaari LI, Niemi M, Neuvonen M, et al. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 2005;78:388-99
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Kajosaari LI, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 2005;77:468-78
   PubMed Web of Science ®Google Scholar
• Niemi M, Leathart JB, Neuvonen M, et al. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther 2003;74:380-7
   PubMed Web of Science ®Google Scholar
• Kalliokoski A, Neuvonen M, Neuvonen PJ, et al. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J Clin Pharmacol 2008
   PubMedGoogle Scholar
• Actos Prescribing Information. Takeda Pharmaceuticals America, Inc.; 2007
   Google Scholar
• Avandia Prescribing Information. GlaxoSmithKline; 2007
   Google Scholar
• Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18
   PubMed Web of Science ®Google Scholar
• Balfour JA, Plosker GL. Rosiglitazone. Drugs 1999;57:921-30; discussion 31-2
   PubMed Web of Science ®Google Scholar
• Gillies PS, Dunn CJ. Pioglitazone. Drugs 2000;60:333-43; discussion 44-5
   PubMed Web of Science ®Google Scholar
• Kalliokoski A, Neuvonen M, Neuvonen PJ, et al. No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. Br J Clin Pharmacol 2008;65:78-86
   PubMed Web of Science ®Google Scholar
• Bluher M, Lubben G, Paschke R. Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care 2003;26:825-31
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Thomas S, Bauer S, et al. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin Pharmacol Ther 2006;80:657-67
   PubMed Web of Science ®Google Scholar
• Tornio A, Niemi M, Neuvonen PJ, et al. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab Dispos 2008;36:73-80
   PubMed Web of Science ®Google Scholar
• Chang C, Pang KS, Swaan PW, et al. Comparative pharmacophore modeling of organic anion transporting polypeptides: a meta-analysis of rat Oatp1a1 and human OATP1B1. J Pharmacol Exp Ther 2005;314:533-41
   PubMed Web of Science ®Google Scholar
• Nozawa T, Sugiura S, Nakajima M, et al. Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug Metab Dispos 2004;32:291-4
   PubMed Web of Science ®Google Scholar
• Shitara Y, Hirano M, Sato H, et al. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug–drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 2004;311:228-36
   PubMed Web of Science ®Google Scholar
• Jaakkola T, Backman JT, Neuvonen M, et al. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther 2005;77:404-14
   PubMed Web of Science ®Google Scholar
• Deng LJ, Wang F, Li HD. Effect of gemfibrozil on the pharmacokinetics of pioglitazone. Eur J Clin Pharmacol 2005;61:831-6
   PubMed Web of Science ®Google Scholar
• Aquilante CL, Bushman LR, Knutsen SD, et al. Influence of SLCO1B1 haplotype on rosiglitazone pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 2008;83:S70
   Google Scholar
• Amaryl Prescribing Information. Aventis Pharmaceuticals, Inc.; 2005
   Google Scholar
• Glucotrol Prescribing Information. Pfizer; 2006
   Google Scholar
• Diabeta Prescribing Information. Aventis Pharmaceuticals, Inc; 2007
   Google Scholar
• Marchetti P, Navalesi R. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update. Clin Pharmacokinet 1989;16:100-28
   PubMed Web of Science ®Google Scholar
• Satoh H, Yamashita F, Tsujimoto M, et al. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 2005;33:518-23
   PubMed Web of Science ®Google Scholar
• Golstein PE, Boom A, van Geffel J, et al. P-glycoprotein inhibition by glibenclamide and related compounds. Pflugers Arch 1999;437:652-60
   PubMed Web of Science ®Google Scholar
• Gedeon C, Behravan J, Koren G, et al. Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta 2006;27:1096-102
   PubMed Web of Science ®Google Scholar
• Lilja JJ, Niemi M, Fredrikson H, et al. Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. Br J Clin Pharmacol 2007;63:732-40
   PubMed Web of Science ®Google Scholar
• Semple CG, Omile C, Buchanan KD, et al. Effect of oral verapamil on glibenclamide stimulated insulin secretion. Br J Clin Pharmacol 1986;22:187-90
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Neuvonen M, et al. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther 2001;69:400-6
   PubMed Web of Science ®Google Scholar
• Zerilli T, Pyon EY. Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Clin Ther 2007;29:2614-34
   PubMed Web of Science ®Google Scholar
• Januvia Prescribing Information. Merck & Co., Inc.; 2007
   Google Scholar
• Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005;78:675-88
   PubMed Web of Science ®Google Scholar
• Chu XY, Bleasby K, Yabut J, et al. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther 2007;321:673-83
   PubMed Web of Science ®Google Scholar
• Precose Prescribing Information. Bayer Pharmaceuticals Corporation; 2004
   Google Scholar
• Glyset Prescribing Information. Pfizer; 2006
   Google Scholar
• Florez JC, Jablonski KA, Bayley N, et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006;355:241-50
   PubMed Web of Science ®Google Scholar
• Ertunc D, Tok EC, Aktas A, et al. The importance of IRS-1 Gly972Arg polymorphism in evaluating the response to metformin treatment in polycystic ovary syndrome. Hum Reprod 2005;20:1207-12
   PubMed Web of Science ®Google Scholar
• Pearson ER, Starkey BJ, Powell RJ, et al. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 2003;362:1275-81
   PubMed Web of Science ®Google Scholar
• Kang ES, Park SY, Kim HJ, et al. Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes. Clin Pharmacol Ther 2005;78:202-8
   PubMed Web of Science ®Google Scholar
• Snitker S, Watanabe RM, Ani I, et al. Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study. Diabetes Care 2004;27:1365-8
   PubMed Web of Science ®Google Scholar
• Kang ES, Park SY, Kim HJ, et al. The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes. Diabetes Care 2005;28:1139-44
   PubMed Web of Science ®Google Scholar
• Wang G, Wang X, Zhang Q, et al. Response to pioglitazone treatment is associated with the lipoprotein lipase S447X variant in subjects with type 2 diabetes mellitus. Int J Clin Pract 2007;61:552-7
   PubMed Web of Science ®Google Scholar
• Kang ES, Cha BS, Kim HJ, et al. The 11482G >A polymorphism in the perilipin gene is associated with weight gain with rosiglitazone treatment in type 2 diabetes. Diabetes Care 2006;29:1320-4
   PubMed Web of Science ®Google Scholar
• Hansen L, Echwald SM, Hansen T, et al. Amino acid polymorphisms in the ATP-regulatable inward rectifier Kir6.2 and their relationships to glucose- and tolbutamide-induced insulin secretion, the insulin sensitivity index, and NIDDM. Diabetes 1997;46:508-12
   PubMedGoogle Scholar
• Sesti G, Marini MA, Cardellini M, et al. The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. Diabetes Care 2004;27:1394-98
   PubMed Web of Science ®Google Scholar
• Meirhaeghe A, Helbecque N, Cottel D, et al. Impact of sulfonylurea receptor 1 genetic variability on non-insulin-dependent diabetes mellitus prevalence and treatment: a population study. Am J Med Genet 2001;101:4-8
   PubMed Web of Science ®Google Scholar
• Rafiq M, Flanagan SE, Patch AM, et al. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care 2008;31:204-9
   PubMed Web of Science ®Google Scholar
• Hansen T, Echwald SM, Hansen L, et al. Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene. Diabetes 1998;47:598-605
   PubMed Web of Science ®Google Scholar
• Hansen T, Ambye L, Grarup N, et al. Genetic variability of the SUR1 promoter in relation to beta-cell function and Type II diabetes mellitus. Diabetologia 2001;44:1330-4
   PubMed Web of Science ®Google Scholar
• Andrulionyte L, Kuulasmaa T, Chiasson JL, et al. Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-alpha gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes 2007;56:1181-6
   PubMed Web of Science ®Google Scholar
• Andrulionyte L, Zacharova J, Chiasson JL, et al. Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia 2004;47:2176-84
   PubMed Web of Science ®Google Scholar
• Andrulionyte L, Laukkanen O, Chiasson JL, et al. Single nucleotide polymorphisms of the HNF4alpha gene are associated with the conversion to type 2 diabetes mellitus: the STOP-NIDDM trial. J Mol Med 2006;84:701-8
   PubMed Web of Science ®Google Scholar
• Zacharova J, Chiasson JL, Laakso M. The common polymorphisms (single nucleotide polymorphism [SNP] +45 and SNP +276) of the adiponectin gene predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes 2005;54:893-9
   PubMed Web of Science ®Google Scholar
• Zacharova J, Todorova BR, Chiasson JL, et al. The G-250A substitution in the promoter region of the hepatic lipase gene is associated with the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. J Intern Med 2005;257:185-93
   PubMed Web of Science ®Google Scholar